Evista gets FDA nod for preventing invasive breast cancer

09/16/2007 | Yahoo!

The FDA approved the osteoporosis drug Evista for the prevention of invasive breast cancer in some groups of high-risk women, drugmaker Eli Lilly & Co. announced Friday. Evista, or raloxifene, has been shown to reduce the risk of breast cancer among postmenopausal women with osteoporosis and among postmenopausal women at high risk for breast cancer by 44%; however, it also had been found to increase their risks for blood clots and stroke.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health